

1 **Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and**
2 **could prevent future surges in some populations: a modeling study**

3 Billy J. Gardner, B.A., A. Marm Kilpatrick, PhD*

4

5 *Department of Ecology and Evolutionary Biology, University of California, Santa Cruz,*
6 *California, USA*

7 **akilpatr@ucsc.edu*

8

9 **Summary**

10 **Background** Vaccines have greatly reduced the impact of COVID-19, but vaccine protection
11 against milder disease and infection have waned significantly, especially for the Delta variant
12 (B.1.617.2). A third booster dose of two-dose vaccines could restore protection but the benefit of
13 boosting immunity in younger healthy individuals and the resultant effects on transmission have
14 not been quantified.

15 **Methods** We develop relationships between neutralizing antibody titers and vaccine protection
16 against both infection and transmission. We combine these relationships with data on waning and
17 boosting of neutralizing antibody titers to examine the impact of third doses of Pfizer-BioNtech
18 and Moderna vaccines on infection and transmission and the impact on the pathogen effective
19 reproductive number R_t .

20 **Findings** Waning reduced protection of the Pfizer-BioNtech vaccine against all infections from
21 80.0% (95% CI: 77% to 83%) to 60.4% (95% CI: 53% to 67%), and for the Moderna vaccine
22 from 83.8 (95% CI: 80 to 87%) to 65.9% (95% CI: 61-71%). A third dose increased neutralizing
23 antibody titers 25.9-fold relative to waned levels for the Pfizer-BioNtech vaccine and 13-fold
24 relative to waned levels for the Moderna vaccine. This increased protection against infection to
25 87.2% (95% CI: 83% to 91%) and 86.3% (95% CI: 82% to 90%) for Pfizer and Moderna,
26 respectively. Increased protection against infection and transmission from third doses reduced R_t
27 by 28% to 74% depending on vaccine coverage and previous infection and reduced R_t below 1
28 when vaccination coverage was high or contact rates were well below pre-pandemic levels.

29 **Interpretation** A third vaccine dose could substantially reduce transmission of SARS-CoV-2
30 and prevent future surges, with the impact increasing with vaccine coverage and contact rates
31 among individuals. Reducing transmission would reduce infection in both unvaccinated
32 individuals and breakthrough infections in vaccinated individuals.

33 **Funding** California Department of Health, National Science Foundation

34 **Keywords** COVID-19; vaccination; waning immunity; herd immunity

35

36 **Introduction**

37 The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 has caused a surge of infections
38 globally, even in populations with high vaccination coverage (1, 2). This is due, in part, to the
39 much higher infectiousness of this virus variant (2, 3), moderate immune evasion (4-6), and,
40 increasingly, waning vaccine immunity. Waning immunity is evident in both levels of
41 neutralizing antibodies (7-10) and studies of vaccine effectiveness (11-13). Several countries
42 have recently offered third doses to individuals at higher risk of severe disease (14) because
43 protection for these individuals, even against severe disease, has waned the most (11). However,
44 protection against severe disease for healthy individuals has waned far less and the need and
45 benefit of providing third doses for young healthy individuals has been questioned (15). Many
46 populations, especially those in Africa, have received very few vaccine doses and many have
47 argued that vaccinating these populations would provide a larger public health benefit than
48 providing third doses to already vaccinated individuals (15) and for reducing the evolutionary
49 potential of the virus (16).

50 While the direct benefit of providing third doses to elderly and other at-risk individuals is now
51 clear (17), the indirect benefit for reducing transmission of SARS-CoV-2 has not been
52 quantified. Most studies examining waning of vaccine effectiveness over time have focused on
53 protection against symptomatic disease (11-13). The impact of waning immunity and boosting
54 on vaccine protection against all infections (symptomatic and asymptomatic) and against virus
55 transmission has been mentioned (15), but not quantified, despite its potential importance for
56 reducing infection in unvaccinated individuals and breakthrough infections in vaccinated
57 individuals.

58 Here we extend a previous approach that showed strong correlations between a measure of
59 immunity, neutralizing antibody titers and vaccine protection (18). This study examined
60 protection against symptomatic disease against non-Delta variants using data from randomized
61 control trials (18). We extend this approach by mapping neutralizing antibody titers to protection
62 against both symptomatic disease and all infections, and against transmission, for both Delta and
63 non-Delta variants. We then use measurements of waning neutralizing antibody titers and
64 boosting with a third dose to estimate the impact on protection against all infections, and the
65 reproductive number of the virus, R_t which quantifies the average number of cases that each case
66 goes on to infect.

67

68 **Methods**

69 *Protection against infection, disease, and transmission*

70

71 We collected data from the literature (including ongoing systematic reviews: (19, 20)) on
72 protective efficacy and effectiveness of vaccines and convalescent sera for SARS-CoV-2 and
73 categorized each study by virus variant type (Delta and non-Delta; estimates of protection
74 against the Beta variant were excluded) and study endpoint (symptomatic infections and all
75 infections) (Table S1). We excluded studies of protection where the endpoint was “any

76 infection” because these studies do not capture all infections and include an unknown fraction of
77 asymptomatic infections. We also obtained an estimate of vaccine effectiveness against
78 transmission (given infection) for Astrazeneca (ChAdOx1) and Pfizer-BioNTech (BNT162b2)
79 vaccines for the Delta variant (21). This study quantified secondary attack rates using qPCR tests
80 of contacts that were symptomatic or tested positive using lateral flow tests (21). It may have
81 missed some asymptomatic or mildly symptomatic infected contacts, and thus provides only a
82 crude estimate of protection. We gathered neutralizing antibody titer data for each vaccine and
83 ratios of titers to convalescent sera from (18). Finally, we estimated the ratio of neutralizing
84 antibody titers to the Delta variant relative to earlier variants (Table S2), and used these to adjust
85 neutralizing antibody titer ratio estimates in analyses with vaccine effectiveness or protection
86 from previous infection against the Delta variant (Table S1).

87

88 *Estimating neutralizing antibody titers after waning and third doses*

89

90 We obtained data on neutralizing antibody titers following vaccination for the Moderna vaccine
91 (9), the Pfizer-BioNTech vaccine, and following infection with SARS-CoV-2 (7) (starting when
92 titers peak at 25 days post symptom onset (22)) at several time points between 1 month after the
93 second dose and 8 months post second dose, as well as 1 month after a third dose (10, 23, 24).
94 One of the studies for the Pfizer vaccine (23) reported data for two age groups separately (18-55
95 and 65+), so we weighted these estimates by the fraction of individuals in the age groups 18-60
96 and 60+ in the United States (71.0% and 29.0%), which is similar to the age distribution in the
97 European Union (25). We fit waning antibody titer data to a 3-parameter exponentially decaying
98 function ($y = c_0 e^{c_1 t} + c_2$) to estimate the neutralizing antibody titer on any day, t , post vaccination
99 (Figure 2; Table S4). We fit several models with additional parameters reflecting differences in
100 the waning rate (c_1) or asymptote (c_2 and c_0) between antibodies derived from the two vaccines
101 or natural immunity. We also estimated waning protection for hybrid immunity following
102 infection and vaccination. Rates of waning for hybrid immunity with Pfizer-BioNtech and
103 Moderna vaccines (combined) were statistically similar to rates of waning following vaccination
104 with Pfizer-BioNtech (8), so we used the same relative rates of waning as for Pfizer-BioNtech
105 (Figure 2; Table S4) but adjusted titers for the 7.9-fold higher initial level in those with hybrid
106 immunity (8). We assumed that boosting individuals that had been infected and then vaccinated
107 resulted in similar neutralizing antibody titers as people that had been vaccinated but not
108 previously infected, because after 6 months of waning post-vaccination, these individuals with
109 hybrid immunity had neutralizing antibody titers that had fallen below levels for newly
110 vaccinated individuals (8).

111

112 *Linking protection against infection and disease with neutralizing antibody titers*

113

114 We modeled the relationship between protection from SARS-CoV-2 infections or disease and the
115 ratio of neutralizing antibody titers relative to convalescent sera using a generalized linear model
116 with a binomial distribution and a logit link, following a previous approach (18). In this analysis
117 each data point is a single study of protection against SARS-CoV-2 infection or disease for a
118 single virus variant. We included an interaction between neutralizing antibody titers and variant-
119 endpoint to estimate separate relationships for each of four variant-endpoints (pairwise
120 combinations of Delta and non-Delta, symptomatic disease, and all infections). We used the
121 separate relationship for the Delta – all infections endpoint for all analyses described below.

122
123 The raw data for each estimate of protection (vaccine efficacy, vaccine effectiveness, or
124 protection from previous infection) were unavailable, so we determined the effective sample
125 sizes for a sample from a binomial distribution that matched the confidence intervals of the
126 protection estimates (Table S1). We used the fitted model (Figure 1) to estimate protection
127 against all infections for the Delta variant for both Moderna and Pfizer - BioNTech vaccines
128 using neutralizing antibody titers measured after 6-8 months of waning and titers measured after
129 a 3rd dose (23, 24). We performed a similar analysis using the limited data available to link
130 neutralizing antibody titers to protection against transmission given infection (21) (Figure S1).

131
132 *The impact of a third dose on the reproductive number, R_t*

133
134 We used patterns of waning and boosting of neutralizing antibody titers and the relationships
135 between neutralizing antibody titers and protection against all infections and transmission to
136 estimate the impact of providing a third dose of Moderna and Pfizer – BioNTech vaccines to
137 increasing fractions of vaccinated individuals on the reproductive number of SARS-CoV-2, R_t .
138 The effective reproductive number, R_t , is the average number of secondary cases that each case
139 infects. It is equal to the basic reproductive number for a fully susceptible population, R_0 ,
140 multiplied by the fraction of the population that is still susceptible. We split the population based
141 on vaccination and infection to determine the effective fraction susceptible: fraction previously
142 infected and unvaccinated, f_{PU} , fraction previously infected and vaccinated, f_{PV} ; fraction
143 unvaccinated, f_U , fraction vaccinated (with two doses of either Pfizer-BioNTech or Moderna), f_V ,
144 and fraction boosted with a third dose, f_B ($f_U+f_V+f_B=1$). We estimated the susceptibility of each
145 group using estimates of the protection against infection, VE_I , (Figure 1) and the reduced
146 probability of transmitting given infection, VE_T , (Figure S1) for each group using the subscripts
147 above, except VE_{IH} and VE_{TH} which are estimates of protection from hybrid immunity from
148 infection and vaccination. We used these estimates of protection to calculate R_t for five groups of
149 people: fully susceptible unvaccinated $(1-f_P)f_U$, previously infected unvaccinated $f_P f_U$, previously
150 uninfected vaccinated $(1-f_P)f_V$, previously infected vaccinated $f_P f_V$, and previously uninfected
151 vaccinated and boosted with a third dose $(1-f_P)f_B$:

152
153
$$R_t = R_0 [(1-f_{PU})f_U + f_{PU}f_U(1-VE_{IP})(1-VE_{TP}) + (1-f_{PV})f_V(1-VE_{IV})(1-VE_{TV}) + (f_{PV}f_V)(1-VE_{IH})(1-$$

154
$$VE_{TH}) + (f_B)(1-VE_{IB})(1-VE_{TB})]$$

155
156 We examined the effect of boosting vaccinated individuals with a third dose by considering five
157 scenarios that differ in contact rates/ R_0 ($R_0 = 3.7$ or 7 reflecting mid-summer 2021 levels in the
158 USA and pre-pandemic behavior, respectively), vaccination coverage (59%, 69%, 75% and
159 100%), and the fraction of the population previously infected (1.0%, 28.5% and 56.9%), with the
160 last value being similar to estimates of the fraction of the USA population that had been infected
161 by late-November, based on 44 million cases and an infection to case ratio of 4.2 (26)). The
162 scenarios and rationale were (Table S5):

- 163
164 1) $R_0 = 3.7$, 59% vaccinated, 56.9% previously infected: approximates USA population in
165 late-November with contact rates similar to summer 2021, as might occur in winter 2021

- 166 2) $R_0 = 3.7$, 69% vaccinated, 1.0% previously infected: approximates countries/populations
167 that effectively suppressed transmission and haven't yet reached high vaccination levels
168 and have somewhat reduced contact rates (e.g. New Zealand, Australia, Hong Kong, etc.)
169 3) $R_0 = 3.7$, 75% vaccinated, 28.5% previously infected: approximates some populations
170 with higher vaccination and lower fraction infected than scenario (1) (e.g. California)
171 4) $R_0 = 7$, 100% vaccinated, 56.9% previously infected: a hypothetical optimistic scenario
172 to compare to scenario (1) to determine if vaccination with or without boosting could
173 limit transmission if behavior returns to pre-pandemic levels
174 5) $R_0 = 7$, 59% vaccinated, 56.9% previously infected: a more realistic scenario to compare
175 to scenario (1) to determine if boosting could limit transmission if behavior returns to
176 pre-pandemic levels
177


178 For all scenarios we estimated the waning of vaccine-derived immunity as of late November,
179 2021 using the timing of vaccination in the USA (27) (Figure S2) and patterns of waning
180 neutralizing antibody titers over time for Pfizer-BioNtech and Moderna vaccines or hybrid
181 immunity (Figure 2). We estimated the waning of infection-derived immunity as of late
182 November, 2021 using the timing of deaths in the USA (25) shifted by 24 days (28) (Figure S3)
183 and the rate of waning of infection-derived immunity (Figure 2). We estimated the number of
184 infections in vaccinated and unvaccinated people using the ratios of cases in these two groups
185 over time in the USA (29) (Figure S4). We used these data on the timing of vaccination and
186 infection and rates of antibody waning to determine the protection against infection and
187 transmission as of late November, 2021 (Table S6). We calculated 95% CIs for predicted values
188 of R_t that incorporated uncertainty in the relationships between neutralizing antibody titers and
189 protection against infection and transmission (Figures 1 and S4). We drew 10,000 samples from
190 a uniform distribution between 0 and 1 and used these as quantiles for a normal distribution to
191 generate draws (on a logit scale) for values of protection VE for each value of neutralizing
192 antibody titer adjusted for waning for the fraction of the population that was vaccinated or
193 infected at each day in the past. This approach essentially drew a single line from the 95% CI of
194 lines in Figure 1 and used that for all levels of waning. We then inverse-logit transformed these
195 values of VE and used them to generate 10,000 values of R_t for that scenario. We took the 2.5%
196 and 97.5% quantiles to estimate the 95% confidence intervals (CIs) for R_t for each point of each
197 scenario.

198

199 **Results**

200 There were very strong relationships between protection against both symptomatic infection and
201 all infections and the ratio of vaccine neutralizing antibody titers relative to convalescent sera
202 (Figure 1; Table S3). Protection was highest for symptomatic disease for non-Delta variants and
203 lower for protection against all infections for both non-Delta and Delta variants (Figure 1; Table
204 S3).


205



206

207 **Fig. 1. Protection against symptomatic infections or all infections plotted against the ratio**
208 **of neutralizing antibody titers relative to convalescent sera. Each round point represents an**
209 **estimate of vaccine efficacy for a single vaccine & virus variant (from randomized control**
210 **trials) or vaccine effectiveness (from observational studies) or an estimate of protection**
211 **from previous infection from observational studies. Square points show predicted values**
212 **using the fitted model and measured neutralizing antibody titers after waning (Moderna: 6**
213 **months; Pfizer 8 months) or boosting. Colors show the SARS-CoV-2 variant (Delta or non-**
214 **Delta) and endpoint of the study (symptomatic infections or all infections). Closed symbols**
215 **and 95% CIs show aggregated data for each vaccine-variant-endpoint. Open symbols show**
216 **estimates from individual studies if there were more than one estimate for a vaccine-**
217 **variant-endpoint. Points have been jittered along the x-axis to facilitate presentation; all**
218 **points for the same vaccine-variant have the same x-value. Lines show fitted models with**
219 **protection as the response and an interaction between and neutralizing antibody ratio and**
220 **variant-endpoint as predictors (Table S3). Panel B shows data and relationships for the**
221 **Delta variant, with all points shifted 2.88-fold lower along the x-axis to reflect the lower**
222 **neutralizing antibodies observed with this variant across studies (Table S2).**

223 Neutralizing antibody titers waned approximately 8-fold for vaccine-derived immunity (for both
224 Pfizer-BioNtech and Moderna vaccines) and 3-fold for infection derived immunity, with fastest
225 waning in the first 3-5 months (Figure 2A, B). Rates of waning were fastest for the Pfizer-
226 BioNtech vaccine, followed by infection-generated antibodies, and antibodies from the Moderna
227 vaccine waned the slowest (Figure 2B; Table S4). Antibodies from infection stabilized at a
228 slightly higher level relative to their peak than either vaccine (Figure 2B), but starting
229 neutralizing antibody titers were lowest for infection, followed by Pfizer-BioNtech and then
230 Moderna (Figure 2A).



231

232 **Figure 2. Waning of neutralizing antibodies and protection against infection over time and**
233 **boosting with third doses. A) Neutralizing antibody titers relative to convalescent sera,**
234 **adjusted for lower neutralization titers with the Delta variant. B) The same data as in panel**
235 **A but rescaled relative to the peak initial value (i.e. all lines start at a value of 1) so rates of**
236 **waning and relative levels of stabilization can be visualized and analyzed simultaneously**
237 **(Table S4). C) Protection against infection over time using the patterns of waning in Panel**
238 **A and the relationships between antibody titers and protection against infection (Figure**
239 **1B, red line). Points in the upper hand corner show the effect of third doses in boosting**
240 **protection for the Pfizer and Moderna vaccines.**


241 We used the strong relationship between neutralizing antibody titers and protection against
242 infection for the Delta variant (Figure 1; Table S3), and patterns of waning of antibody titers
243 (Figure 2A, B) to estimate the waning of protection against all infections over time (Figure 2C).
244 Protection against all infections was highest for Hybrid immunity (infection followed by
245 vaccination), followed by Moderna, Pfizer-BioNtech vaccines, and then infection-derived
246 immunity. The relatively fast and sustained waning rate of neutralizing antibodies for the Pfizer-
247 BioNtech vaccine suggests that protection from this vaccine was initially much higher than
248 infection-derived immunity but the two were similar after four months (Figure 2C). Specifically,
249 waning of neutralizing antibody titers reduced protection against all infections for the Delta
250 variant for the Pfizer-BioNtech vaccine from 80.0% (95% CI: 77.0% to 83.0%) to 60.4% (95%
251 CI: 53.3% to 67.2%) (Figure 2, purple line and Figure 1, red line, compare points labelled
252 “Pfizer orig” to “Pfizer waned”). Waning of neutralizing antibodies also reduced the protection
253 against transmission given infection for the Pfizer-BioNtech vaccine from 38% (95% CI: 28% to
254 47%) to 10.5% (95% CI: 6.6% to 16.4%) (Figure S1).

255 A third dose of the Pfizer-BioNtech vaccine boosted antibody titers 26-fold relative to levels
256 after 8 months of waning, or $25.9/8.1 = 3.2$ -fold higher than one week after dose 2 (23). A third
257 dose of the Moderna vaccine boosted antibody titers 13-fold relative to waned levels, or 1.5-fold
258 higher than after the 2nd dose. The fitted relationship between protection and antibody titers
259 (Figure 1; Table S3) suggests third doses of the Pfizer-BioNtech vaccine would increase
260 protection against infection from an eight-month waned value of 60.4% (95% CI: 53.3% to
261 67.2%) to a boosted value of 87.2% (95% CI: 82.8% to 90.7%) (Figure 2C) and would boost
262 protection against transmission given infection from 10.5% to 60.7% (95% CI: 42.3% to 76.5%)
263 (Figure S1). For the Moderna vaccine, a third dose would increase protection against infection
264 from a waned value of 65.8% (60.9-70.5%) to a boosted value of 86.3% (82.0-89.7%), and
265 would increase protection against transmission (given infection) from a waned value of 14.9%
266 (10.8-20.2%) to a boosted value of 57.2% (40.3-72.6%) (Figure S1).

267 Next, we examined the impacts of third doses on population level transmission. Boosting
268 immunity, by providing a third dose of the Pfizer-BioNtech vaccine to all doubly vaccinated
269 individuals in the USA (59% of the total population), could reduce the reproductive number R_t
270 by 28% from 1.26 to 0.91 and stop a surge (Figure 3, red line), assuming current levels of
271 vaccination coverage (59%), estimated immunity from previous infection (56.9%), and behavior
272 consistent with the summer Delta surge ($R_0=3.7$) (see Methods for further details).
273 Unfortunately, in places where vaccination is slightly higher (69%), but previous infection is
274 much lower, (1.0%; e.g. New Zealand), boosting with a third dose would be unable to prevent a
275 surge with the same contact rates (Figure 3, grey line). Conversely, in populations where
276 vaccination is higher (75%) and previously infection is lower (28.5%) (e.g. California), boosting
277 at least 50% of the population (67% of those vaccinated) could push R_t below 1 (Figure 3 blue
278 line).

279 If contact rates return to pre-pandemic levels ($R_0=7$), with late November USA vaccine coverage
280 (59%) and infection history (56.9%), then boosting could reduce R_t by a larger absolute amount
281 (but the same relative amount, 28%) than with lower contact rates, from 2.38 to 1.72 (Figure 3,

282 green line) but cases would still rise rapidly because 1.72 is still far above 1. Using the same
283 number of 3rd doses to doubly vaccinate unvaccinated individuals would be more impactful, and
284 could reduce R_t to 1.49 (Figure 3, compare right end of green line to black point labelled 88.5%
285 vaccinated on left side). If contact rates return to pre-pandemic levels ($R_0=7$), then even if a
286 population had 100% vaccination coverage and 56.9% previously infected, waning of vaccine
287 and infection-derived immunity would cause cases to continue to grow without boosting (Figure
288 3, left end of yellow line: $R_t=1.33$ which is greater than 1; without waning R_t would be 0.80, well
289 below 1). However, boosting at least 34% of a fully (100%) vaccinated population would reduce
290 R_t below 1 and thus could prevent a surge in cases, even with pre-pandemic behavior (Figure 3,
291 yellow line); boosting the entire population with a third dose would reduce R_t by 74% (from 1.33
292 to 0.35). Note that three scenarios (Fig 3, red, blue, and yellow lines, representing moderate
293 vaccination and infection, high vaccination and low infection, and complete vaccination and
294 moderate infection but pre-pandemic behavior, respectively) all produce similar values of R_t ,
295 because vaccination and infection contribute similarly to immunity after waning (Figure 2C), and
296 very high immunity (through vaccination or infection) is needed to balance pre-pandemic
297 behavior.



298

299 **Figure 3. Relationship between third dose coverage and the pathogen effective reproductive**
300 **number, R_t . Lines and 95% CIs show the estimated reproductive number for five scenarios**
301 **(see Methods). The single black point shows the impact of using all third doses from the**
302 **right end of the green line to doubly-vaccinate unvaccinated individuals, which would**
303 **bring the vaccination coverage from 59% to 88.5%. Protection from vaccination and**
304 **previous infection for all lines reflect waning, as described in the Methods (Table S3). The**
305 **dashed horizontal line shows the threshold reproductive number $R_t = 1$, separating a**
306 **growing from a shrinking epidemic.**

307

308 Discussion

309 Vaccines have greatly reduced the impact of COVID-19 globally, but waning immunity and the
310 emergence of the Delta variant have led to surges in cases despite high vaccination coverage in
311 many populations (1, 7-10). This has led to many countries recommending third doses to boost
312 immunity to protect at-risk individuals (14). However, the impact of third doses on transmission
313 of SARS-CoV-2 has received far less attention (15), and no study has empirically estimated the
314 impact of third doses on infection, transmission, and the reproductive number R_t .

315 We found that a third dose could substantially reduce transmission, especially in highly
316 vaccinated populations, and the absolute effect was larger when contact rates (which scale R_0)
317 were higher. We showed that neutralizing antibodies are strongly correlated not just with
318 protection against symptomatic disease (4, 18), but also with protection against all infection and
319 transmission given infection (Figures 1, S4). These relationships allowed us to estimate the effect
320 of waning and boosting on transmission, and the pathogen reproductive number R_t . Boosting
321 immunity by providing a third dose to individuals vaccinated more than three months ago (after
322 most waning has occurred: Figure 2) could reduce transmission substantially and could prevent a
323 winter surge in many populations where vaccination coverage is high, as long as contact rates
324 and behavior don't fully return to pre-pandemic levels. In contrast, with pre-pandemic contact
325 rates, only very high levels of vaccine coverage, and a combination of a moderate level of
326 previous infection and boosting could prevent a surge.

327 We also found that despite the substantial potential impact of boosting on transmission,
328 deploying vaccine doses to unvaccinated individuals has a larger effect on transmission (Figure
329 3, compare the black point to the right end of the green line). In addition, the direct effect of
330 vaccinating unvaccinated people is much larger than the benefit of providing a third dose for
331 severe disease and death since protection against severe disease has only waned slightly, except
332 in older or at-risk individuals (11). Unfortunately, vaccine hesitancy among those not vaccinated
333 is quite high in many populations (e.g., USA, Russia, etc.) and many people are unwilling to get
334 vaccinated despite strong incentives, often due to misinformation (30-32), making it difficult to
335 increase vaccine coverage in some populations. In contrast, there other populations where
336 vaccine coverage is very low, primarily due to poor availability, especially in parts of Africa
337 (33). Clearly, limited vaccine doses would be most effectively used in these populations and
338 should be deployed there until supplies are no longer limiting.

339 Our study has several limitations. First and foremost is the reliance on neutralizing antibody
340 titers as a predictor of protection against infection and transmission. Although the analyses here,
341 and elsewhere suggest a strong relationship between neutralizing antibody titers and protection at
342 the population level (4, 18) and individual level (34), other parts of the immune system, such as
343 T-cells, also play key roles in protection, especially against severe disease. Second, our analyses
344 use population averages for estimates of protection against infection and transmission and ignore
345 age-specific variation among individuals (as well as other factors). Third, the data available to
346 estimate vaccine protection against all infections and against transmission given infection from
347 the Delta variant was limited. Fourth, it's unclear how long antibody titers will be elevated
348 following a third dose, so the effect of boosting might not last long. Finally, we assume well-

349 mixed populations in calculating reductions in the reproductive number R_t . Clearly a targeted
350 vaccination approach would be more effective than that outlined here if individuals that were
351 highly connected could be targeted for third doses (35).

352 In summary, many countries have already begun to deploy third doses to protect at-risk
353 individuals, and some countries (e.g. Israel, the UK, and the USA (17)) have started to deploy
354 third doses to the general population. However, uptake in most countries has been low, criteria
355 for third doses have been vague and confusing (14), and only moderate effort has been expended
356 to deploy third doses widely. Our results suggest that widespread boosting of the general
357 population could substantially reduce transmission. Polls in some countries suggest a large
358 fraction of the vaccinated population would be willing to get a third dose (e.g., 76% of
359 Americans; (36)). If vaccine doses for providing initial doses to populations with very low
360 coverage are not limiting, then offering third doses to the general public could play a significant
361 role in reducing transmission. This would directly protect boosted individuals (37), indirectly
362 protect unvaccinated and vaccinated individuals, and reduce the possibilities for viral evolution
363 (16).

364

365 **Contributors**

366 AMK conceived the study. BJG and AMK performed the analyses and wrote the paper.

367 **Declaration of interests**

368 All authors declare no competing interests.

369 **Data sharing**

370 Code and data files to replicate the figures and analyses of this paper can be found at:

371 <https://github.com/marmkilpatrick/Vaccine-boosters>

372 **Acknowledgements**

373 We thank the Kilpatrick lab for helpful comments.

374 **References**

- 375 1. Wadman M. Israel's grim warning: Delta can overwhelm shots. *Science*.
376 2021;373(6557):838-9.
- 377 2. Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, et al. Exponential growth,
378 high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.
379 *Science*.0(0):eabl9551.
- 380 3. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al.
381 Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.
382 *Eurosurv*. 2021;26(24):2100509.
- 383 4. van Gils MJ, Lavell AHA, van der Straten K, Appelman B, Bontjer I, Poniman M, et al.
384 Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-
385 CoV-2 variants. *medRxiv*. 2021:2021.09.27.21264163.

- 386 5. Davis C, Logan N, Tyson G, Orton R, Harvey W, Haughney J, et al. Reduced
387 neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
388 medRxiv. 2021:2021.06.23.21259327.
- 389 6. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
390 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*.
391 2021;596(7871):276-80.
- 392 7. Havervall S, Marking U, Gordon M, Ng H, Greilert-Norin N, Lindbo S, et al.
393 Neutralization of VOCs including Delta one year post COVID-19 or vaccine. medRxiv.
394 2021:2021.08.12.21261951.
- 395 8. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al.
396 mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
397 *Science*. 2021:eabm0829.
- 398 9. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al.
399 Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-
400 19. *N Engl J Med*. 2021;384(23):2259-61.
- 401 10. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune
402 humoral response to BNT162b2 covid-19 vaccine over 6 months. *N Engl J Med*. 2021.
- 403 11. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine
404 effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and
405 severe COVID-19 in the UK. medRxiv. 2021.
- 406 12. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Haas E, et al.
407 Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. medRxiv. 2021.
- 408 13. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al.
409 Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *N Engl J*
410 *Med*. 2021.
- 411 14. Furlong A, Deutsch J. A country-by-country guide to coronavirus vaccine booster plans
412 2021 [Available from: [https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-](https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-europe-delta-varian-who/)
413 [europe-delta-varian-who/](https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-europe-delta-varian-who/)].
- 414 15. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al.
415 Considerations in boosting COVID-19 vaccine immune responses. *Lancet* (London, England).
416 2021;398(10308):1377-80.
- 417 16. Wagner CE, Saad-Roy CM, Morris SE, Baker RE, Mina MJ, Farrar J, et al. Vaccine
418 nationalism and the dynamics and control of SARS-CoV-2. medRxiv. 2021.
- 419 17. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al.
420 Protection of BNT162b2 vaccine booster against covid-19 in Israel. *N Engl J Med*.
421 2021;385(15):1393-400.
- 422 18. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
423 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
424 SARS-CoV-2 infection. *Nat Med*. 2021:1-7.
- 425 19. Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic
426 review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and
427 disease. medRxiv. 2021:2021.09.17.21263549.
- 428 20. WHO. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic
429 Review 2021 [Available from: [https://view-hub.org/sites/default/files/2021-](https://view-hub.org/sites/default/files/2021-09/COVID19%20VE%20Studies_Forest%20Plots_1.pdf)
430 [09/COVID19%20VE%20Studies_Forest%20Plots_1.pdf](https://view-hub.org/sites/default/files/2021-09/COVID19%20VE%20Studies_Forest%20Plots_1.pdf)].

- 431 21. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of
432 SARS-CoV-2 vaccination on Alpha and Delta variant transmission. medRxiv.
433 2021:2021.09.28.21264260.
- 434 22. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al.
435 Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living
436 review. *Ann Intern Med.* 2021;174(6):811-21.
- 437 23. Falsey AR, Frenck Jr RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-
438 CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med.* 2021.
- 439 24. Chu L, Montefiori D, Huang W, Nestorova B, Chang Y, Carfi A, et al. Immune Memory
440 Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome
441 Coronavirus-2 (SARS-CoV-2). medRxiv. 2021:2021.09.29.21264089.
- 442 25. CDC. COVID Data Tracker 2021 [Available from: [https://covid.cdc.gov/covid-data-
443 tracker/#vaccinations_vacc-total-admin-rate-total](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total)].
- 444 26. CDC. Estimated COVID-19 Burden 2021 [Available from:
445 <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>].
- 446 27. CDC. COVID-19 Vaccinations in the United States 2021 [Available from:
447 https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total].
- 448 28. Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence,
449 clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California
450 and Washington: prospective cohort study. *BMJ-British Medical Journal.* 2020;369:10.
- 451 29. CDC. Rates of COVID-19 Cases and Deaths by Vaccination Status 2021 [Available
452 from: <https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status>].
- 453 30. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrahi M, Zigron A, et al. Vaccine
454 hesitancy: the next challenge in the fight against COVID-19. *Eur J Epidemiol.* 2020;35(8):775-9.
- 455 31. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of
456 vaccine acceptance rates. *Vaccines.* 2021;9(2):160.
- 457 32. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. *Nat Med.*
458 2021;27(8):1338-9.
- 459 33. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of
460 COVID-19 vaccine in low-income countries. *npj Vaccines.* 2021;6(1):1-3.
- 461 34. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, et al. Immune
462 Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv.
463 2021:2021.08.09.21261290.
- 464 35. Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world
465 network to model localized COVID-19 control strategies. *Nat Med.* 2020;26(10):1616-22.
- 466 36. Aboulenein A, Kahn C. Most vaccinated Americans want COVID-19 booster shots -
467 Reuters/Ipsos poll: Reuters; 2021 [Available from: [https://www.reuters.com/business/healthcare-
468 pharmaceuticals/most-vaccinated-americans-want-covid-19-booster-shots-reutersipsos-poll-
469 2021-09-01/](https://www.reuters.com/business/healthcare-pharmaceuticals/most-vaccinated-americans-want-covid-19-booster-shots-reutersipsos-poll-2021-09-01/)].
- 470 37. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of
471 a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in
472 Israel: an observational study. *The Lancet.* 2021.
- 473 38. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness
474 of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection
475 and severe covid-19 outcomes in Ontario, Canada: test negative design study. *BMJ.*
476 2021;374:n1943.

- 477 39. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA
478 Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384(15):1412-
479 23.
- 480 40. Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of
481 ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.
482 1.1. 7): an exploratory analysis of a randomised controlled trial. *The Lancet*.
483 2021;397(10282):1351-62.
- 484 41. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine
485 coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine
486 against infection (SIREN): a prospective, multicentre, cohort study. *The Lancet*.
487 2021;397(10286):1725-35.
- 488 42. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
489 Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. *N Engl J Med*.
490 2021:585-94.
- 491 43. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et
492 al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and
493 hospitalisation, Navarre, Spain, January to April 2021. *Eurosurv*. 2021;26(21):2100438.
- 494 44. Narrainen F, Shakeshaft M, Asad H, Holborow A, Blyth I, Healy B. The protective effect
495 of previous COVID-19 infection in a high-prevalence hospital setting. *Clinical Medicine*.
496 2021;21(5):e470.
- 497 45. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of
498 COVID-19 vaccines against variants of concern, Canada. *Medrxiv*. 2021.
- 499 46. Pouwels KB, Pritchard E, Matthews P, Stoesser NB, Eyre DW, Vihta K-D, et al. Impact
500 of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the
501 UK. *medRxiv*. 2021.
- 502 47. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of
503 vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med*. 2021:1-9.
- 504 48. Satwik R, Satwik A, Katoch S, Saluja S. ChAdOx1 nCoV-19 effectiveness during an
505 unprecedented surge in SARS COV-2 infections. *European Journal of Internal Medicine*. 2021.
- 506 49. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane F, Al Khatib HA, et al.
507 BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2)
508 variant in Qatar. *MedRxiv*. 2021.
- 509 50. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-
510 dose administration and the influence of the timing of the booster dose on immunogenicity and
511 efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
512 *The Lancet*. 2021;397(10277):881-91.
- 513 51. Whitaker H, Tsang R, Byford R, Andrews N, Sherlock J, Pillai P. Pfizer-BioNTech and
514 Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals
515 in clinical risk groups. *Khub net* Posted July. 2021.
- 516 52. Richardson JR, Goetz R, Mayr V, Lohse MJ, Holthoff H-P, Ungerer M. SARS-COV2
517 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after
518 infection. *medRxiv*. 2021.
- 519 53. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody
520 activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. *The*
521 *Lancet*. 2021;397(10292):2331-3.

522 54. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Ability of AZD1222
523 vaccination to elicit neutralising antibodies against SARS-CoV-2 VOC B. 1.617. 2 (Delta).
524 Lancet (London, England). 2021;398(10296):207.

525

526

527

528 **Supplemental Tables and Figures**

529 **Table S1. Data and studies used to estimate the relationship between protection (VE)**
 530 **against infection, disease and transmission endpoints and neutralizing antibody titer (NAT)**
 531 **ratios relative to convalescent sera (Figure 1). A single value of the neutralizing antibody**
 532 **titer ratio was used for each vaccine and variant; values for the Delta variant are 2.88-fold**
 533 **lower than for non-Delta variants (Table S2). N_{eff} are the effective sample sizes used for the**
 534 **logistic regression (Table S3).**

Study	Vaccine or Convalescent	Variant	Endpoint	NAT Ratio	VE (95% CI)	N_{eff}
(13)	Moderna	non-Delta	Symptomatic	4.13	0.99 (0.92-1.00)	70
(38)	Moderna	non-Delta	Symptomatic	4.13	0.94 (0.86-0.97)	112
(38)	Pfizer	non-Delta	Symptomatic	2.37	0.91 (0.88-0.93)	550
(39)	Pfizer	non-Delta	Symptomatic	2.37	0.94 (0.87-0.98)	96
(40)	Astrazeneca	non-Delta	Symptomatic	0.54	0.75 (0.42-0.89)	16
(21)	Astrazeneca	Delta	Transmission	0.19	0.16 (0.12-0.21)	243
(21)	Pfizer	Delta	Transmission	0.82	0.38 (0.28-0.47)	109
(41)	Convalescent	non-Delta	All infections	1	0.83 (0.76-0.87)	168
(41)	Pfizer	non-Delta	All infections	2.37	0.86 (0.76-0.97)	49
(18)	Astrazeneca	non-Delta	Symptomatic	0.54	0.62 (0.41-0.76)	34
(18)	Convalescent	non-Delta	Symptomatic	1	0.89 (0.66-0.98)	18
(18)	CoronaVac	non-Delta	Symptomatic	0.17	0.50 (0.36-0.62)	60
(18)	JJ	non-Delta	Symptomatic	0.47	0.67 (0.59-0.74)	147
(18)	Moderna	non-Delta	Symptomatic	4.13	0.94 (0.89-0.97)	150
(18)	Novovac	non-Delta	Symptomatic	3.97	0.96 (0.68-0.99)	25
(18)	Pfizer	non-Delta	Symptomatic	2.37	0.95 (0.90-0.98)	200
(18)	Sputnik	non-Delta	Symptomatic	1.41	0.92 (0.85-0.95)	140
(42)	Astrazeneca	Delta	Symptomatic	0.19	0.67 (0.61-0.72)	330
(42)	Astrazeneca	non-Delta	Symptomatic	0.54	0.75 (0.68-0.79)	240
(42)	Pfizer	Delta	Symptomatic	0.82	0.88 (0.85-0.90)	750
(42)	Pfizer	non-Delta	Symptomatic	2.37	0.94 (0.92-0.95)	720
(43)	Pfizer	non-Delta	Symptomatic	2.37	0.82 (0.73-0.88)	110
(44)	Convalescent	non-Delta	All infections	1	0.97 (0.81-1.00)	25
(45)	Astrazeneca	non-Delta	Symptomatic	0.54	0.91 (0.62-0.98)	22
(45)	Astrazeneca	Delta	Symptomatic	0.19	0.87 (0.69-0.95)	32
(45)	Moderna	non-Delta	Symptomatic	4.13	0.92 (0.88-0.95)	225
(45)	Moderna	non-Delta	Symptomatic	4.13	0.96 (0.85-0.99)	50
(45)	Moderna	Delta	Symptomatic	1.44	0.95 (0.91-0.97)	220
(45)	Pfizer	non-Delta	Symptomatic	2.37	0.89 (0.86-0.91)	1440
(45)	Pfizer	Delta	Symptomatic	0.82	0.92 (0.90-0.94)	600
(45)	Pfizer	non-Delta	Symptomatic	2.37	0.93 (0.88-0.95)	210
(46)	Astrazeneca	Delta	All infections	0.19	0.67 (0.62-0.71)	420
(46)	Astrazeneca	non-Delta	All infections	0.54	0.79 (0.56-0.90)	25

(46)	Convalescent	Delta	All infections	0.35	0.72 (0.58-0.82)	53
(46)	Convalescent	non-Delta	All infections	1	0.60 (0.50-0.68)	125
(46)	Pfizer	Delta	All infections	0.82	0.80 (0.77-0.83)	780
(46)	Pfizer	non-Delta	All infections	2.37	0.78 (0.68-0.84)	100
(47)	Astrazeneca	non-Delta	All infections	0.54	0.79 (0.65-0.88)	50
(47)	Pfizer	non-Delta	All infections	2.37	0.80 (0.73-0.85)	185
(48)	Convalescent	Delta	Symptomatic	0.35	0.93 (0.87-0.96)	169
(49)	Moderna	Delta	Symptomatic	1.44	0.86 (0.71-0.94)	42
(49)	Pfizer	Delta	Symptomatic	0.82	0.56 (0.41-0.67)	64
(50)	Astrazeneca	non-Delta	All infections	0.54	0.56 (0.41-0.67)	63
(51)	Astrazeneca	non-Delta	Symptomatic	0.54	0.78 (0.70-0.84)	150
(51)	Pfizer	non-Delta	Symptomatic	2.37	0.93 (0.86-0.97)	100

535

536 **Table S2. Ratios of neutralizing antibody titers to Delta or non-Delta variants of SARS-**
 537 **CoV-2 from vaccination or infection SARS-CoV-2.**

Reference	non-Delta variant	Sample type	Ratio non-Delta to Delta
(4)	D614G	Pfizer-BioNtech	4.5
(4)	D614G	Astrazeneca	4.5
(23)	Wild Type	Pfizer-BioNtech	1.28
(5)	Wuhan	Pfizer-BioNtech	11.30
(5)	Wuhan	Astrazeneca	4.01
(52)	Wild Type	Pfizer-BioNtech	2.1
(52)	Wild Type	Astrazeneca	2.1
(53)	Wild Type	Pfizer-BioNtech	5.8
(54)	Wild Type	Astrazeneca	8.0
(7)	Wild Type	Pfizer-BioNtech	1.18
(7)	Wild Type	Astrazeneca	1.22
(6)	D614G	Pfizer-BioNtech	2.0
(6)	D614G	Astrazeneca	5.0
(4)	D614G	Convalescent	2.1
(6)	D614G	Convalescent	2.1
		Estimated ratio*	2.88

538 *There was no significant difference in the ratios among sample types (either vaccines or
 539 convalescent sera): mixed effects model of log-transformed ratio with Sample Type as a fixed
 540 effect and study as a random effect; likelihood ratio $\chi^2(df=2) = 2.6$; $P = 0.26$.

541

542

543 **Table S3. Logistic regression analysis of protection (vaccine efficacy or effectiveness or**
 544 **protection from previous infection) with the log-transformed ratio of neutralizing antibody**
 545 **titers (NAT-Ratio) relative to convalescent sera, with an interaction with four groups for**
 546 **variant (Delta and non-Delta) and endpoint (symptomatic cases or all infections) as shown**
 547 **in Figure 1. Delta – infection was the reference level.**

Predictor	Estimate	SE	Z-value	P-value
Intercept	1.47	0.10	14.49	<0.0001
log ₂ (NAT-Ratio)	0.32	0.064	4.97	<0.0001
non-Delta – symptomatic	0.10	0.11	0.87	0.39
non-Delta – infection	-0.41	0.13	-3.00	0.0027
Delta – symptomatic	0.77	0.13	5.79	<0.0001
log ₂ (NAT-Ratio):non-Delta - symptomatic	0.27	0.076	3.59	0.00034
log ₂ (NAT-Ratio):non-Delta - infection	-0.035	0.12	-0.29	0.77
log ₂ (NAT-Ratio):Delta - symptomatic	0.22	0.089	2.50	0.012

548

549 **Table S4. Analysis of waning rates of neutralizing antibodies for two vaccines (Pfizer-**
 550 **BioNtech and Moderna) and infection-derived immunity. The best fitting model by AIC**
 551 **was Antibody titer = (c₀+c₇*Infection)*e^(c₁*Day+c₃*Day*Moderna+c₄*Infection*Day)+c₂+c₆*Infection,**
 552 **where Pfizer-BioNtech was the reference level. There was no support for Moderna having a**
 553 **different asymptote than Pfizer (P-values>0.45 for coefficients similar to c₇ and c₆).**

Coefficient	Estimate	SE	t-value	P-value
c ₀	0.91	0.037	24.61	<0.0001
c ₁	-0.022	0.0027	-8.25	<0.0001
c ₂	0.10	0.032	3.22	0.0074
c ₃	0.011	0.0023	4.653	0.0006
c ₄	0.0083	0.0052	1.58	0.14
c ₆	0.20	0.054	3.64	0.0034
c ₇	-0.21	0.074	-2.81	0.0157

554

555

556 **Table S5. Fraction of the population in each group for the five scenarios in Figure 3, using**
 557 **the case ratios in vaccinated and unvaccinated individuals and the timing of vaccinations**
 558 **and infections derived from COVID-19 deaths and vaccinations as of late November, 2021**
 559 **in the USA (Figures S2-S4).**

Scenario	Fraction vaccinated and infected ($f_{PV} * f_V$)	Fraction vaccinated and not infected ($((1-f_{PV}) * f_V)$)	Fraction unvaccinated and infected ($f_{PU} * f_U$)	Fraction fully susceptible ($((1-f_{PU}) * f_U)$)
R0=3.7; 59% vacc., 56.9% prev. inf.	0.27	0.32	0.29	0.12
R0=3.7; 69% vacc., 1.0% prev. inf.	0.0035	0.69	0.0065	0.30
R0=3.7; 75% vacc., 28.5% prev. inf.	0.18	0.57	0.11	0.14
R0=7; 100% vacc., 56.9% prev. inf.	0.569	0.431	0	0
R0=7; 59% vacc., 56.9% prev. inf.	0.27	0.32	0.29	0.12


560

561 **Table S6. Estimated protection (and 95% CI) against infection (VE_I) and transmission**
 562 **(VE_T) given waning of vaccine and infection derived immunity, as of late November, 2021**
 563 **in the USA, using case ratios in vaccinated and unvaccinated individuals and the timing of**
 564 **vaccinations and infections derived from COVID-19 deaths and vaccinations (Figures S2-**
 565 **S4). These estimates are derived from the rates of waning of neutralizing antibody titers**
 566 **(Figure 2; Table S4) and the relationship between neutralizing antibody titers and**
 567 **protection against infection for Delta (Figure 1; Table S3) and transmission given infection**
 568 **(Figure S1).**

Endpoint	Estimate with waning (95% CI)
VE_{IP} (infected and unvaccinated)	0.614 (0.552-0.670)
VE_{TP} (infected and unvaccinated)	0.123 (0.086-0.178)
VE_{IV} (vaccinated and uninfected)	0.647 (0.603-0.690)
VE_{TV} (vaccinated and uninfected)	0.155 (0.124-0.195)
VE_{IV} (vaccinated and uninfected) NZ scenario	0.708 (0.669-0.744)
VE_{TV} (vaccinated and uninfected) NZ scenario	0.222 (0.173-0.280)
VE_{IH} (vaccinated and infected)	0.813 (0.781-0.841)
VE_{TH} (vaccinated and infected)	0.425 (0.320-0.530)
VE_{IB} (boosted with third dose)	0.872 (0.828-0.907)
VE_{TB} (boosted with third dose)	0.607 (0.423-0.765)

569

570




571

572 **Figure S1. Protection against transmission given infection plotted against the ratio of**
573 **neutralizing antibody titers relative to convalescent sera from infection with SARS-CoV-2**
574 **for AstraZeneca (left filled triangle) and Pfizer (right filled triangle) (21). The raw data is in**
575 **Table S1 – Transmission endpoint. Open squares show the estimated protection with**
576 **waning (left open square) and boosting (right open square). The fitted model is:**
577 **logit(Protection) = -0.336 (±0.225) + 0.549 (±0.124) * log₂(neut. antibody ratio); P<0.0001.**

578


579



580

581 **Figure S2. Number of people fully vaccinated in the USA (27).**


582



583

584 **Figure S3. COVID-19 cases, deaths, and infections inferred from deaths in the USA (25).**

585



586

587 **Figure S4. Ratio of COVID-19 cases in unvaccinated individuals relative to vaccinated**
588 **individuals in the USA in 2021 based on data from CDC (29). Points show weekly**
589 **estimates, and the line and ribbon shows a generalized additive model fit and 95% CI.**

590